Envision Solar Closes $2.5M in Equity Funding to add to $4.5M in Debt and Working Capital Completing the Company's Current Funding Initiatives

SAN DIEGO, CA—(Marketwired – January 16, 2018) – Envision Solar International, Inc., (OTCQB: EVSI) (“Envision Solar,” or the “Company”), the leading renewably energized EV charging, outdoor media and energy security products company, announced that it has closed its fundraising efforts on the successful completion of a $2.5M equity raise. The Company previously announced $1.5M in term debt and $3M in working capital credit to fund the execution of the Company's record backlog of orders for its EV ARC™ product.

The $2.5M equity raise, which was priced at or close to market and without any other dilutive provisions, will be used to continue the Company's increased sales and marketing investments and to fund ongoing expenses through a period of what management believes will be significant growth. The $3M in working capital will be used to execute the Company's existing backlog and growing pipeline.

Envision is currently delivering products to New York City and various California governmental organizations through multi–year contract vehicles as well as continuing to service enterprise and other government customers such as a major automotive OEM and educational and governmental institutions.

In November of 2017, Outfront Media Inc. (NYSE: OUT) announced an agreement with Envision to partner in the deployment of networks of EV ARC™ products in major US cities starting in San Diego.

“Completing this fundraising effort allows us to continue with the serious business of growing the Company,” said Desmond Wheatley, President and CEO of Envision Solar. “All the macro indicators suggest that the industry opportunities we are pursuing keep getting richer. We are in a strong position to take advantage of those opportunities and we have the best products for growth, scale and rapid deployment.”

“Envision is an innovative company with unique products addressing rapidly growing segments,” said Peter Davidson, CEO of Aligned Intermediary, former Director of DOE's loan program and Envision board member. “We have been able to attract sophisticated investors to this last round of financing because the company and its products have matured and because of the team's demonstrated ability to win new business from top tier business and industry customers and to deliver on those orders.”

The California Energy Commission estimates that the state will require around 174,000 EV charging stations to meet Governor Brown's goal of 1.5M EVs on the state's roads by 2025. Current grid–tied charging installations take an average of 9 to 18 months to install and generate significant utility bills. Envision's EV ARC™ EV charging product can be deployed in less than 10 minutes and provides a lifetime of free and clean energy. The Company views California's requirements as a significant opportunity and useful indicator of the scale of opportunity across the US and the rest of the world in the coming months and years. Envision has a multi–year mandatory contract with the State of California to supply its EV ARC™ product.

About Envision Solar International, Inc.

Envision Solar, www.envisionsolar.com, is a sustainable technology innovation company who's unique and patented products include the EV ARC™ and the Solar Tree® with EnvisionTrak™ patented solar tracking, SunCharge™ solar Electric Vehicle Charging, ARC™ technology energy storage and EnvisionMedia solar advertising displays.

Based in San Diego the company produces Made in America products. Envision Solar is listed on the OTC Bulletin Board under the symbol [EVSI]. For more information, visit www.envisionsolar.com or call (866) 746–0514.

Forward–Looking Statements

This Press Release may contain forward–looking statements regarding future events or our expected future results that are subject to inherent risks and uncertainties. All statements in this Report other than statements of historical facts are forward–looking statements. Forward–looking statements are generally accompanied by terms or phrases such as “estimate,” “project,” “predict,” “believe,” “expect,” “anticipate,” “target,” “plan,” “intend,” “seek,” “goal,” “will,” “should,” “may,” or other words and similar expressions that convey the uncertainty of future events or results. Statements contemplating or making assumptions regarding actual or potential sales, market size and demand, prospective business contracts, customer orders, trends or operating results also constitute forward looking statements. Our actual results may differ substantially from those indicated in forward looking statements because our business is subject to significant economic, competitive, regulatory, business and industry risks which are difficult to predict and many of which are beyond our control. Our operating results, financial condition and business performance may be adversely affected by a general decline in the economy, unavailability of capital or financing for our prospective customers to purchase products and services from us, competition, changes in regulations, a decline in the demand for solar energy, a lack of profitability, a decline in our stock price, and other risks. We may not have adequate capital, financing or cash flow to sustain our business or implement our business plans. Current results and trends are not necessarily indicative of future results that we may achieve.

Timbercreek 2018 Global Real Estate Securities Outlook Report: Global REITs Expected to Deliver 8-10 Percent Returns

TORONTO, ON—(Marketwired – January 11, 2018) –

  • Higher realizable rents, completion of development projects and new property acquisitions driving growth
  • Canada: Office and retail REITs capitalizing on urban growth
  • U.S.: The technology sector gaining momentum, driving up rent and demand for data centres

Timbercreek today released its 2018 Market Outlook which identifies key trends the firm anticipates for global real estate securities in the year ahead. Overall, the report predicts strong performance across many markets including Canada and the United States, with global Real Estate Investment Trusts (REITs) expected to deliver returns of between 8–10 percent.

“We anticipate that this year's market conditions will be favourable for global real estate securities as valuations remain attractive, both on an absolute and a relative basis, with global REITs trading below the 10–year global equities average — levels not seen since 2008–2009,” stated Corrado Russo, Senior Managing Director, Investments & Global Head of Securities, Timbercreek. “These factors, when combined with projected dividend growth should positively influence global REIT share prices in 2018.”

Within the Canadian real estate sector, the report notes the following:

  • The outlook for the sector remains positive, particularly for REITs that own office and retail assets with infill development opportunity in urban areas such as Toronto, Montreal and Vancouver.
  • REITs are expected to add value on existing properties by creating mixed–use assets where each use — retail, residential and office — virtuously support each other.
  • Timbercreek believes Canadian small cap REITs and REITs that own assets internationally (in Europe or the U.S.) are fundamentally mispriced and poised to deliver better than average returns in 2018.

“Large cities in Canada are currently experiencing a wave of gentrification driven by people's desire to live, work and play in walkable, urban environments,” said Mr. Russo. “This is creating a number of compelling opportunities for REITs to experience outsized growth and offer increasing value for investors.”

The report also predicts a positive overall outlook for the U.S., based on the following considerations:

  • The technology sector is a top investment opportunity for 2018 as data centres continue to gain momentum which should drive up market rents and increase the demand.
  • Survivors within bricks and mortar retail — specifically high quality retail centres in strong locations and non–discretionary grocery–anchored shopping centres that are trading at discounts — present opportunities to earn attractive dividend yields and generate outsized total returns.
  • The lodging sector represents a compelling source of upside for 2018 driven by improving U.S. GDP growth that is forecasted to accelerate to 2.7 percent and corporate tax reform that has the potential to loosen travel budgets which have been reined–in since the financial crisis.
  • The outlook for the single family rental sector is expected to experience strong cyclical growth opportunities to earn above average total returns in 2018, in part due to a tax reform plan that penalizes home ownership in high tax markets.

“In the U.S., home prices continue to rise, prompting growth in the rental market led by millennials,” said Mr. Russo. “Beyond this, secular growth opportunities exist in the world of technology, value plays in lodging and strong cyclical growth in single family rentals.”

Highlights – Other Markets:

  • U.K. & Continental Europe: Economic and property fundamentals continue to improve and broaden with GDP growth in Ireland, Spain, Germany and Sweden forecasted to be at around 3 percent in 2018. The underperformance of European retail REITs — in the bricks and mortar and residential sectors — is expected to offer investors the opportunity to generate higher than average dividend yields.
  • Japan: Recent underperformance of Japanese real estate companies have made valuations more compelling heading into 2018. Further, economic conditions are improving led by small and medium business growth, accelerating prices, higher industrial production and rising employment.
  • Hong Kong: Office companies with a strong presence in decentralized submarkets such as Admiralty and Island East are favourable and anticipated to benefit from growing demand for high quality international tenants coming out of Central.
  • Australia: Australia is expected to generate attractive income from smaller sized REITs that invest in niche–oriented sectors such as education, entertainment and self–storage. In the office sector, Sydney and Melbourne remain pillars of strength.

“We believe global real estate fundamentals remain strong, with global REITs priced to deliver another year of positive total returns as suggested by our bottom–up fundamental analysis,” Mr. Russo concluded.

To view the report, please visit: http://www.timbercreek.com/quick–links/white–papers

About Timbercreek

Timbercreek is an active investor, owner and manager of global real estate and related assets focused on delivering sustainable and growing returns to our investors. Through our various separately managed accounts, TSX–listed entities and private investments, Timbercreek (together with its affiliates) manages over $7.5 billion[1] (CAD) in assets on behalf of investors seeking quality alternative asset class investments. Timbercreek employs a value–oriented investment philosophy, which is combined with an active, hands–on asset management style, to identify opportunities that will generate predictable and sustainable investment returns for our investors.

The Timbercreek 2018 Global Real Estate Securities Outlook Report and the content of this press release are for informational purposes only and are not an offer or solicitation to deal in securities. Any opinion or estimate contained in these documents is made on a general basis and is not to be relied upon for the purpose of making investment decisions. The statements made herein may contain forecasts, projections or other forward–looking information regarding the likelihood of future events or outcomes in relation to financial markets or securities. These statements are only predictions. Actual events or results may differ materially, as past or projected performance is not indicative of future results. Readers must make their own assessment of the relevance, accuracy and adequacy of the information contained in these documents and such independent investigations as they consider necessary or appropriate for the purpose of such assessment. These documents do not constitute investment research. Consequently, these documents have not been prepared in line with the requirements of any jurisdiction in relation to the independence of investment research or any prohibition on dealing ahead of the dissemination of investment research. Any research or analysis used in the preparation of these documents has been procured by Timbercreek for its own use. The information is not guaranteed as to its accuracy.

[1] Includes syndicated debt under administration. As of November 30, 2017.

Take a timeout2vote for Your Favorite NCAA Coach in the INFINITI Coaches' Charity Challenge

NASHVILLE, TN—(Marketwired – January 08, 2018) –

  • INFINITI introduces new #timeout2vote campaign to launch eighth–annual Coaches' Charity Challenge
  • From January to March, 48 NCAA® basketball coaches compete to raise $349,000 for local charities
  • Fan votes determine winning coach receiving a $100,000 donation from INFINITI

INFINITI kicks off the most exciting season for college basketball with the “INFINITI Coaches' Charity Challenge” and a new creative campaign that encourages fans to take a #timeout2vote for their favorite coaches and charities.

The INFINITI Coaches' Charity Challenge is a unique aspect of the brand's partnership with the National Association of Basketball Coaches (NABC), the NCAA® and ESPN. At the start, 48 NCAA® Division I men's basketball coaches compete for fan votes in a four–round contest that raises money for charities of the coaches' choice.

INFINITI, an official corporate partner of the NCAA, will make donations throughout the competition totaling $349,000. The further the coaches advance in the competition, the more money they raise for their respective charities. The winning coach will receive $100,000 to benefit his charity of choice.

“The INFINITI Coaches' Charity Challenge provides the perfect platform for college basketball coaches and fans to work as a team, providing significant financial support and awareness for so many worthy charitable initiatives,” said Jim Haney, NABC executive director. “Numerous national and local charitable organizations are the beneficiaries of the outstanding contributions made throughout the year by college basketball coaches across the country.”

While only one coach will win the grand prize, INFINITI has guaranteed each coach a donation of at least $1,000 to his chosen charitable organization.

Take a timeout2vote

Beginning Jan. 2, fans will decide the winner over a 10–week period by casting votes at www.infinititimeout.com. Supporters can cast one vote per day for a coach's charity. For the first time, basketball fans will be able to vote via Instagram and Twitter using the hashtag #timeout2vote.

“Every year INFINITI looks forward to working with NABC, NCAA® and ESPN to raise money for charities with the INFINITI Coaches' Charity Challenge,” said Phil O'Connor, director, Marketing Communications and Media. “This year, our campaign focuses on the importance of timeouts both on and off the court, and we encourage fans to take a timeout from their daily lives to vote for their favorite coaches and their respective charities.”

The first round of voting takes place Jan. 2 and runs through Jan. 21, with half of the coaches advancing to a second round, held between Jan. 22 and Feb. 11. From Feb. 12 to 25, the 16 advancing coaches from round two will compete in a third round where only four coaches advance to the final, fourth round which takes place from Feb. 26 to March 10. The coach with the most votes, along with his chosen charity, will be announced on March 11.

“The INFINITI Coaches' Charity Challenge is a very successful program that connects our fan base and college coaches in a fun way to worthy organizations and foundations in local communities,” said Ellen Lucey, NCAA director of championships and alliances, corporate relations, marketing and brand. “We're pleased to be involved with the challenge this year as the program represents a way to return the support that is given to our member schools and our student–athletes.”

The challenge is further promoted across the ESPN digital and broadcast network including ESPN, ESPN2, ESPNU, ESPN.com and across several social media platforms.

The 48 coaches participating this year:

  • University of Alabama coach Avery Johnson, competing for Coaches vs. Cancer
  • University of Arizona coach Sean Miller, competing for Casa de los Niños
  • Arizona State University coach Bobby Hurley, competing for Pat Tillman Foundation
  • Auburn University coach Bruce Pearl, competing for Children's Harbor, Inc.
  • Baylor University coach Scott Drew, competing for Coaches vs. Cancer
  • BYU coach Dave Rose, competing for BYU Simmons Center for Cancer Research
  • Central Florida University coach Johnny Dawkins, competing for Boys and Girls Club of Central Florida
  • Clemson University coach Brad Brownell, competing for The Outdoor Dream Foundation
  • University of Colorado coach Tad Boyle, competing for Special Olympics Colorado
  • Creighton University coach Greg McDermott, competing for Abide
  • University of Florida coach Mike White, competing for UF Health Shands Children's Hospital
  • Georgia State University coach Ron Hunter, competing for Samaritan's Feet International
  • Georgia Tech coach Josh Pastner, competing for WellStar Foundation
  • Gonzaga University coach Mark Few, competing for Community Cancer Fund
  • University of Illinois coach Brad Underwood, competing for United Way of Champaign County
  • University of Indiana coach Archie Miller, competing for Indiana University Dance Marathon
  • University of Iowa coach Fran McCaffery, competing for Coaches vs. Cancer
  • Iowa State University coach Steve Prohm, competing for Lupus Foundation of America, Iowa Chapter
  • Kansas State University coach Bruce Weber, competing for Coaches vs. Cancer
  • LSU coach Will Wade, competing for Baton Rouge Youth Coalition
  • Marquette University coach Steve Wojciechowski, competing for Camp Hometown Heroes
  • University of Maryland coach Mark Turgeon, competing for Alzheimer's Association
  • University of Memphis coach Tubby Smith, competing for Tubby Smith Foundation
  • Michigan State University coach Tom Izzo, competing for Volunteers of America Michigan
  • University of Missouri coach Cuonzo Martin, competing for Boys & Girls Club of Columbia, Missouri
  • University of North Carolina coach Roy Williams, competing for UNC Lineberger Comprehensive Cancer Center
  • University of Notre Dame coach Mike Brey, competing for Coaches vs. Cancer
  • University of Oklahoma coach Lon Kruger, competing for Coaches vs. Cancer
  • University of Oregon coach Dana Altman, competing for Children's Miracle Network (CMN)
  • Providence College coach Ed Cooley, competing for Amos House
  • Purdue University coach Matt Painter, competing for Smith Family BReaK Thru Fund
  • University of South Carolina coach Frank Martin, competing for South Carolina Center for Fathers and Families
  • St. John's University coach Chris Mullin, competing for The Herren Project
  • St. Louis University coach Travis Ford, competing for Big Brothers Big Sisters of Eastern Missouri
  • Stanford University coach Jerod Haase, competing for Lucile Packard Children's Hospital Stanford
  • Stephen F. Austin State University coach Kyle Keller, competing for Nacogdoches Area United Way
  • Syracuse University coach Jim Boeheim, competing for Jim and Juli Boeheim Foundation
  • Texas Christian University coach Jamie Dixon, competing for Maggie Dixon Foundation
  • Temple University coach Fran Dunphy, competing for Big Brothers Big Sister Independence
  • University of Tennessee coach Rick Barnes, competing for Emerald Youth Foundation
  • UCLA coach Steve Alford, competing for Special Olympics Southern California
  • Vanderbilt University coach Bryce Drew, competing for Coaches vs. Cancer
  • Villanova University coach Jay Wright, competing for Augustinian Fund
  • University of Virginia coach Tony Bennett, competing for American Red Cross Virginia Region
  • Wake Forest University coach Danny Manning, competing for Special Olympics North Carolina
  • University of West Virginia coach Bob Huggins, competing for Norma Mae Huggins Cancer Research Endowment Fund
  • Wichita State University coach Gregg Marshall, competing for Wichita Children's Home
  • University of Wisconsin coach Greg Gard, competing for Garding Against Cancer

INFINITI Motor Company Ltd. is headquartered in Hong Kong with representations in 50 markets around the world. The INFINITI brand was launched in 1989. Its range of premium automobiles is currently built in manufacturing facilities in Japan, the United States, United Kingdom and China. INFINITI design studios are located in Atsugi–Shi (near Yokohama), London, San Diego and Beijing. INFINITI is in the middle of a major product offensive. The brand has been widely acclaimed for its daring design and innovative driver–assistance technologies. From the 2016 season, INFINITI is a technical partner of the Renault Sport Formula One team, contributing its expertise in hybrid performance.

More information about INFINITI and its industry–leading technologies can be found at www.infiniti.com. You can also follow INFINITI on Facebook, Instagram, Twitter, LinkedIn and see all our latest videos on YouTube.

About NCAA
The NCAA is a membership–led nonprofit association of colleges and universities committed to supporting academic and athletic opportunities for more than 450,000 student–athletes at more than 1,000 member colleges and universities. Each year, more than 54,000 student–athletes compete in NCAA championships in Divisions I, II and III sports. Visit www.ncaa.org and www.ncaa.com for more details about the Association, its goals, members and corporate partnerships that help support programs for student–athletes. [NCAA is a trademark of the National Collegiate Athletic Association.]

About the National Association of Basketball Coaches
Located in Kansas City, Missouri, the NABC was founded in 1927 by Forrest “Phog” Allen, the legendary basketball coach at the University of Kansas. Allen, a student of James Naismith, the inventor of basketball, organized coaches into this collective group to serve as Guardians of the Game. The NABC currently has nearly 5,000 members consisting primarily of university and college men's basketball coaches. All members of the NABC are expected to uphold the core values of being a Guardian of the Game by bringing attention to the positive aspects of the sport of basketball and the role coaches play in the academic and athletic lives of today's student–athletes. The four core values of being a Guardian of the Game are advocacy, leadership, service and education. Additional information about the NABC, its programs and membership, can be found at www.nabc.org.

Image Available: http://www.marketwire.com/library/MwGo/2018/1/8/11G149267/Images/Timeout_Social_Infiniti_Static_FB–Twitter_V4–8c7e5639a2708fbb91d95eab4fcbb56f.jpg

Advanced Proteome Therapeutics and Heidelberg Pharma Progress Collaborative Program

VANCOUVER, BC and LADENBURG, GERMANY—(Marketwired – January 08, 2018) – Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and Heidelberg Pharma announced today advances in their collaborative activities. The companies have agreed to test the combination of APC's proprietary site–selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology in order to generate superior cancer therapeutics.

Since the inception of the partnership, activities have been centered on antibody–amanitin conjugates that are produced using controlled conjugation methods and possess high target–specific cytotoxic potency. The companies have successfully demonstrated the generation of ATACs using APC's proprietary protein modification technology.

“In a first step, we have succeeded in producing ADCs that are sufficiently cytotoxic to target–expressing cancer cell lines to proceed to the next level of in vivo testing. Results obtained from this collaboration will help us to increase the efficacy of our ATACs”, commented Professor Andreas Pahl, CSO of Heidelberg Pharma.

“We are delighted that the partnership with Heidelberg Pharma has generated positive results and look forward to continuing our work together, to the benefit of both companies”, commented Randal Chase, CEO of Advanced Proteome Therapeutics.

APC's technology aims at the coupling of a cytotoxic payload site–selectively to an antibody of interest without the necessity of genetically engineering such antibody. This may lead to more homogeneous products with certain additional advantages such as an increase in stability in the circulation, fewer side effects and facilitating further pre–clinical and clinical drug development.

About Advanced Proteome Therapeutics

Advanced Proteome Therapeutics Corporation (APC) (TSX VENTURE: APC) (FRANKFURT: 0E8) is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity, and lower toxicity than other therapies that can also attack healthy cells. Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential. www.advancedproteome.com

About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third–party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP–101 is a BCMA ATAC for multiple myeloma. The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON® and REDECTANE®, while RENCAREX® is available for out–licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg–pharma.com.

Heidelberg Pharma

Heidelberg Pharma AG

Sylvia Wimmer

Tel.: +49 89 41 31 38–29

Email: investors[at]hdpharma.com

Schriesheimer Str. 101, 68526 Ladenburg
IR/PR support

MC Services AG

Katja Arnold (CIRO)

Managing Director & Partner

Tel.: +49 89–210 228–40

Email: katja.arnold[at]mc–services.eu

Heidelberg Pharma Research GmbH

Business Development

Dr. Marcel Linssen
CBO, Executive Vice President

Tel.: +49 6203 1009–40

Email: m.linssen[at]hdpharma.com


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This communication contains certain forward–looking statements relating to the Company's business, which can be identified by the use of forward–looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company's strategies, plans or intentions. Such forward–looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward–looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward–looking statements. We disclaim any obligation to update any such forward–looking statements to reflect future events or developments.

TopiVert Pharma Limited: Positive results from TOP1288 Phase 1 study

LONDON, UNITED KINGDOM—(Marketwired – Jan 8, 2018) – TopiVert Pharma Ltd

TopiVert announces positive results from the Phase 1 study with its oral formulation of TOP1288 for the treatment of ulcerative colitis

London, UK, 8 January 2018: TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical–stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally–acting medicines for the treatment of chronic inflammatory gastrointestinal and ocular diseases, today announces positive data from its Phase 1 study (TV03) with its oral formulation of TOP1288 for the treatment of ulcerative colitis (UC).

UC is a form of inflammatory bowel disease (IBD) affecting the colon. As many as 40% of patients fail to respond to current drug therapy, which is also often poorly tolerated, and around 15% of patients may still require surgical removal of the colon to manage the disease. TOP1288 is a NSKI developed by TopiVert that targets several important kinases in inflammatory cells, leading to synergistic inhibition of key signalling pathways involved in innate and adaptive immunity. TOP1288 also has very low systemic bioavailability such that its activity is confined to the site of active disease in UC patients and thus provides an improved safety and tolerability profile.

TV03 was a randomised, double–blind, placebo–controlled Phase 1 study to assess safety, tolerability, pharmacokinetics and pharmacodynamic responses to single and multiple oral doses of TOP1288. Employing an innovative trial design, individual subjects received serial sigmoidoscopies so that multiple colon biopsies could be obtained to allow the direct measurement of tissue drug concentrations, as well as markers of target engagement and pharmacodynamic responses, from colon tissue.

The results demonstrated that TOP1288 was being delivered to the colon with drug detected in tissue biopsies up to 36 hours after last dose. In addition, dose–dependent positive effects on markers of target engagement and biomarker responses were seen (in cells taken from colon tissue), indicating that the measured concentrations were pharmacologically relevant. TOP1288 was also found to be safe and well tolerated when administered orally with minimal systemic absorption being noted, confirming results from prior studies.

In parallel, a proof of mechanism study in UC patients comparing TOP1288 and placebo, both delivered as a liquid enema, has also reported. Clinically relevant changes from baseline were seen in the TOP1288 arm for all endpoints but due to a large response in the placebo arm, including for centrally read endoscopic endpoints, the efficacy assessment was uninterpretable.

Based upon the strong data from the TV03 study, TopiVert is preparing to progress the oral TOP1288 formulation into a proof of concept study in UC.

Ajay Duggal, TopiVert's Chief Medical Officer, commented: “We are delighted with the clinical progress made with our TOP1630 and TOP1288 NSKI programmes in ophthalmology and IBD respectively. Our recently reported strong proof of concept data for TOP1630 in dry eye syndrome validates our NSKI technology in the treatment of inflammatory disease. For our IBD program, using an innovative trial design, we have successfully demonstrated that drug can be delivered into the colon tissue at pharmacologically relevant concentrations. This is an exciting time for TopiVert as we look forward to progressing the clinical development of both our lead programmes in areas of high unmet medical need.”

Professor Simon Travis, (Professor of Clinical Gastroenterology, University of Oxford), commented: “These results put TopiVert in a unique position in the development of oral topical anti–inflammatories for treatment of IBD. The colon biomarker and PK data generated with the oral formulation of TOP1288, together with the fact that there was minimal systemic absorption, demonstrate effects through truly local action. This phenomenon has not been demonstrated before. Although efficacy still needs to be established, the results obtained strongly support progression to the next stages of development”


For more information, please contact:

TopiVert Pharma Ltd   info@topivert.com
Steve Webber, Chief Scientific Officer   +44 (0)7824 395449
Nick Staples, Chief Business Officer    
Ajay Duggal, Chief Medical Officer    
Consilium Strategic Communications   topivert@consilium–comms.com
Mary–Jane Elliott / Ivar Milligan   +44 (0)20 3709 5700

About TopiVert
TopiVert is a clinical–stage biotechnology company developing narrow spectrum kinase inhibitors as novel, locally–acting medicines for the treatment of chronic inflammatory gastrointestinal (GI) and ocular diseases. The Company's lead GI programme, TOP1288 for the treatment of ulcerative colitis, has recently demonstrated strong safety, PK and PD data in a Phase 1 study with an oral formulation. The Company's lead ophthalmology programme, TOP1630 for dry eye syndrome (DES), has also reported compelling results in a Phase 1/2a proof of concept study in the US. Current therapies for these debilitating inflammatory diseases provide inadequate long–term control in a high proportion of patients and considerable unmet medical need remains. The Company commenced operations in early 2012 and its investors include SV Health Investors, Touchstone Innovations, NeoMed and Johnson & Johnson Innovation – JJDC, Inc.

About Narrow Spectrum Kinase Inhibitors (NSKIs)
NSKIs are novel small molecules characterised by broad, potent anti–inflammatory activity and minimal systemic exposure. Specifically, NSKIs are potent inhibitors of a select range of pivotal kinases involved in inflammatory cascades of both innate and adaptive immunities. Simultaneous targeting of multiple inflammatory components leads to a synergistic activity profile with broad anti–inflammatory effects. NSKIs are designed to have low systemic bioavailability so that their exposure to the body's healthy tissues is reduced, thereby providing enhanced safety and tolerability. Together, these attributes make NSKIs ideal treatment candidates for chronic inflammatory diseases where long term therapy demands a sustained effect accompanied by excellent safety and tolerability.

About IBD and ulcerative colitis
Inflammatory bowel disease (IBD) is a term used to describe several diseases that involve inflammation of the gastrointestinal tract. The two most common forms of IBD, Crohn's disease and ulcerative colitis, together affect over 4 million people worldwide. They are both chronic relapsing conditions that cause bloody diarrhoea, abdominal pain and significant reductions in a patient's quality of life. While their causes are not fully understood, these diseases are characterised by an abnormal inflammatory reaction that leads to damage of the intestinal wall.

Current treatments for ulcerative colitis involve administration of oral, rectal or intravenous/ subcutaneous anti–inflammatory and immunomodulatory therapies, including biologics. Despite these products being effective in treating active disease in some patients, their long–term use is often hampered by safety and tolerability issues. Furthermore, at least 40% of patients have poorly controlled disease and around 15% may require surgery to manage the disease.

About Dry Eye Syndrome
Dry eye syndrome (DES), also known as dry eye disease, keratoconjunctivitis sicca (KCS) or keratitis sicca, is an inflammatory eye disease characterised by dryness on the surface of the eye. It is usually a chronic problem and it can be debilitating in severe cases. It is also one of the most common eye diseases, with almost 19 million sufferers in the US alone and over 300 million worldwide1. DES becomes more common with age, with a third of elderly people suffering from this ailment.

[1] Market Scope®, 2013 Report on the Global Market for Dry Eye Products

This information is provided by RNS
The company news service from the London Stock Exchange

In its Annual Best Places Issue, Sunset Announces its List of 20 Towns that “Redefine the West”

OAKLAND, CA—(Marketwired – January 02, 2018) – Sunset, the defining lifestyle brand of the modern American West, has announced its list of “20 Game–Changers That Are Redefining the West” as part of its annual “Best Places” issue. The article can be found in the February issue of the magazine, on newstands now, as well as online at https://www.sunset.com/bestplaces2018.

“The West was founded by pioneers and continues to evolve thanks to that same pioneering spirit as forward–thinking opportunity seekers transform cities and towns into hubs of innovation, big and small,” said Irene Edwards, Sunset Editor–in–Chief. “This year's Best Places to Live list celebrates the places that are thinking smart about their futures, from innovative community leaders to futuristic tech and small business incubators.”

In the February issue, Sunset's editors find 20 examples of cities and towns that exemplify the best of Western living for today and tomorrow. The winners in each region include:

  • Northern California: Sacramento, CA (runners up: Eureka, CA; Fresno, CA; Truckee, CA)
    • Sunset editors noted Sacramento “is giving city dwellers a taste of both town and country” thanks to its city gardening programs and farm–to–table dining.”
  • Southern California: Carlsbad, CA (runners up: Culver City, CA; Palm Springs, CA; Oxnard, CA)
    • According to the editors, Carlsbad is a “digital hub [that] has upped its game to embrace both its inner geek and outdoor enthusiast.”
  • Mountains: Salida, CO (runners up: Missoula, MT; Cochrane, Alberta; Reno, NV)
    • Salida was rediscovered when “people realized they could buy a Victorian for a steal, and artists could spend their time creating instead of working an office job,” Sunset's editors reveal.
  • Southwest: Albuquerque, NM (runners up: Taos, NM; Flagstaff, AZ; Tempe, AZ)
    • “Considering the strong public–art program, miles of hiking trails, and 310 annual days of sunshine, it's no wonder the locals don't boast. They're too busy living,” write Sunset's editors on their reasons for choosing Albuquerque.
  • Northwest: Tacoma, WA (runners up: Corvallis, OR; Sisters, OR; Spokane, WA)
    • Tacoma's revitalization “is years in the making” note Sunset editors, thanks in part to an influx of creative makers who are taking advantage of the city's industrial warehouses to create incubators and establish new businesses.

The roundup of “20 Game–Changers That Are Redefining the West” also features personal stories of local residents. Readers will also find compelling facts on each city including population, median home value, percentage of tree coverage, and number of farmers markets and parks.

“Every year, Sunset embarks on a search for the best places in the West. This year our search began by identifying maverick towns and cities beyond perennial centers of change such as Los Angeles and San Francisco,” explained Sunset Executive Editor Lauren Ladoceour. “Once we found the towns and cities investing in tomorrowland industries, community models, and ideas, we crunched the numbers, like census data, housing prices, and jobs, to determine value and livability. Our final step is to dig into the soul of a place by asking community leaders and families who've recently moved there: What makes your town the best?”

Interviews with Sunset editors and photography are available upon request. For more information, visit Sunset on Facebook, Twitter, Instagram and Pinterest

About Sunset

SUNSET (http://www.sunset.com) is the defining lifestyle brand of the modern American West. Through magazines and books, events and experiences, and digital and social media, the iconic 120–year–old brand covers the region's top destinations, food and wine experiences, home and garden trends, and personalities. SUNSET engages and inspires an audience of more than 6.5 million educated, active and affluent consumers every month through its five regional print editions–Northern California, Southern California, Pacific Northwest, Southwest, and Mountain–as well as via all tablet devices and its website. In addition to its print and digital publications, SUNSET showcases the West's unique lifestyle and compelling destinations through its flagship events, established home programs, licensing partnerships, books and International Wine Competition.

Image Available: http://www.marketwire.com/library/MwGo/2017/12/27/11G149126/Images/tll0218b–hr4100–59902–ts–ad0c46562cf7b1508513ec239716e86e.jpg
Image Available: http://www.marketwire.com/library/MwGo/2017/12/27/11G149126/Images/tll0218b–hr3901–59902–ts–893702613e1f8362ac5d6a2d09a4b048.jpg